Potential Cialis switch and the pending addition of Boehringer Ingelheim's consumer business are the revenue drivers highlighted by company execs on earnings call; second-quarter consumer health product revenues slipped 4.3% to $886.4m as a mild allergy season in the US and economic chaos in Venezuela drag down sales.
Sanofi is working to "fine-tune" an application to make erectile dysfunction drug Cialis available OTC in the US, marking another potential boost for its consumer health care segment on top of adding Boehringer Ingelheim GMBH's consumer business.
After Sanofi's second-quarter consumer health product revenues slipped 4.3% to €800m ($886.4m) as a mild allergy season in the US and economic chaos in Venezuela dragged down sales, the French...
The budget authority total, which is significantly higher than the amount floated in an April OMB draft document, suggests there may have been successful lobbying to increase FDA funding.
In this first in a series of articles looking at the potential impact of the MFN drug pricing policy on European pharmaceutical markets, EUCOPE’s Alexander Natz tells the Pink Sheet why the US policy underscores the importance of confidential net pricing.
The lack of a formal analysis of efficacy in castration-resistant prostate cancer patients without HRR mutations doomed Pfizer’s Talzenna at the US FDA's Oncologic Drugs Advisory Committee, as FDA oncology chief Richard Pazdur says chance cannot be ruled out.
